Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | BCHE | P06276 | 2/20 | 0.51 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.51 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.51 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.50 |
| ▸ | ACHE | P22303 | 8/20 | 0.47 |
| ▸ | PRCP | P42785 | 1/20 | 0.43 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29991483 | 0.95 | GNAI3 (0.57) | GAABCHEGNAI3GNAO1GNAI1 | |
| SCHEMBL9544590 | 0.94 | GNAI3 (0.60) | GAABCHEGNAI3GNAO1GNAI1 | |
| SCHEMBL3647096 | 0.91 | GAA (0.56) | GAABCHEGNAI3GNAO1GNAI1 | |
| SCHEMBL29990844 | 0.90 | EPHX1 (0.50) | GAABCHEGNAI3GNAO1GNAI1 | |
| SCHEMBL8487311 | 0.86 | ACHE (0.57) | GAAGNAI3GNAO1GNAI1EPHX1 | |
| SCHEMBL8243750 | 0.85 | GAA (0.63) | GAABCHEEPHX1ACHEKCNA3 | |
| SCHEMBL22134964 | 0.85 | EPHX1 (0.66) | GAABCHEEPHX1ACHE | |
| SCHEMBL30407733 | 0.85 | GAA (0.59) | GAABCHEEPHX1ACHE | |
| SCHEMBL22136179 | 0.83 | EPHX1 (0.69) | GAABCHEEPHX1ACHE | |
| SCHEMBL2801495 | 0.83 | EPHX1 (0.69) | GAABCHEEPHX1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101899058-A | Method for preparing thiazolopyrimidine compound and application thereof | FOURTH MILITARY MEDICAL UNIV | 2010-12-01 | — | — | CN | claimed |
| CN-103193773-B | Pyridyloxyindoles inhibitors of VEGF-R2 and their use for treating diseases | NOVARTIS AG | 2014-12-10 | — | — | CN | disclosed |
| CN-102307870-B | Pyridyloxyindoles inhibitors of VEGF-R2 and their use for treating diseases | NOVARTIS AG | 2014-06-18 | — | — | CN | disclosed |
| CN-101932577-B | Heteroaryl-substituted piperidines | BAYER HEALTHCARE AG | 2013-07-17 | — | — | CN | disclosed |
| CN-103193773-A | Pyridyloxyindoles inhibitors of VEGF-R2 and their use for treating diseases | NOVARTIS AG | 2013-07-10 | — | — | CN | disclosed |
| CN-101068794-B | Quinazolines useful as modulators of ion channels | VERTEX PHARMA | 2012-12-19 | — | — | CN | disclosed |
| CN-1882568-B | Pyrrol derivatives with antibacterial activity | ASTRAZENECA AB | 2012-03-28 | — | — | CN | disclosed |
| CN-102307870-A | Pyridyloxyindoles inhibitors of VEGF-R2 and their use for treating diseases | NOVARTIS AG | 2012-01-04 | — | — | CN | disclosed |
| CN-101932577-A | Heteroaryl-substituted piperidines | BAYER HEALTHCARE AG | 2010-12-29 | — | — | CN | disclosed |
| CN-101899058-A | Method for preparing thiazolopyrimidine compound and application thereof | FOURTH MILITARY MEDICAL UNIV | 2010-12-01 | — | — | CN | disclosed |
| US-7494992-B2 | Antiparasitic terpene alkaloids | PFIZER INC. (US) | 2009-02-24 | — | — | US | disclosed |
| CN-101277951-A | 2-aminopyrimidine derivatives as modulators of the histamine H4 receptor activity | PALAU PHARMA SA (ES) | 2008-10-01 | — | — | CN | disclosed |
| CN-101068794-A | Quinazolines useful as modulators of ion channels | VERTEX PHARMA (US) | 2007-11-07 | — | — | CN | disclosed |
| US-20070185101-A1 | Antiparasitic terpene alkaloids | PFIZER PRODUCTS INC | 2007-08-09 | — | — | US | disclosed |
| CN-1882568-A | Pyrrol derivatives with antibacterial activity | ASTRAZENECA AB (SE) | 2006-12-20 | — | — | CN | disclosed |
| EP-1597264-A2 | ANTIPARASITIC TERPENE ALKALOIDS | Pfizer Limited (GB) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004072086-A2 | ANTIPARASITIC TERPENE ALKALOIDS | PFIZER LIMITED (GB) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185101-A1 | Antiparasitic terpene alkaloids | CYP51A1, DHPS, CYP8B1 | GAA 945/4885BCHE 36/4885GNAI3 2204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.